Review Article

Digitizing Quality: Trends and Regulatory Challenges in eQMS Adoption in the Pharmaceutical Sector

Dr. Nikhil Arun Vyawhare*

Quality Assurance Manager, Quality Assurance, SM Pharmaceuticals Sdn Bhd, Sungai Petani Industrial Estate, Sungai Petani, Kedah – 08000, Malaysia.

***Corresponding author's E-mail:** nikhilvyawhare@gmail.com

Received: 22-05-2025; **Revised:** 26-08-2025; **Accepted:** 08-09-2025; **Published online:** 20-09-2025.

ABSTRACT

This paper explores the how electronic Quality Management Systems (eQMS) are changing the pharmaceutical industry. The need to improve product quality, operational efficiency, and regulatory compliance drives this change. It discusses the basic benefits of eQMS, such as automation and real-time data access. It also covers new technology trends like Artificial Intelligence, the Internet of Things, cloud computing, and blockchain that are changing quality standards. The paper focuses on the complex global regulatory landscape. It details guidelines from USFDA, EMA, ICH, WHO, PIC/S, MCC/SAHPRA, and ANVISA related to data integrity and computerized system validation. Additionally, it examines how to use and validate common eQMS tools like LIMS, SAP Quality Management, and TrackWise. The paper ends by highlighting the crucial role of thorough software validation and ongoing compliance with changing global guidelines. This ensures the reliability and integrity of digital quality processes, which ultimately protects patient safety and product effectiveness.

Keywords: eQMS, Pharmaceutical Quality, Software Validation, Data Integrity, Regulatory Compliance, Digital Transformation.

INTRODUCTION

The pharmaceutical industry faces strict regulatory oversight because product quality directly impacts patient safety and public health. Maintaining consistent quality, safety, and effectiveness of medicinal products from research and development to manufacturing, distribution, and post-market monitoring is essential. Traditionally, quality management has relied on paper-based systems. While these systems are foundational, they often cause significant issues with efficiency, data access, and audit preparation. These old methods can be slow, vulnerable to human error, and hard to scale, especially in a global and increasingly complex supply chain.

The limitations of manual processes have led to a necessary shift toward more dynamic, integrated, and digital solutions. Using electronic Quality Management Systems (eQMS) signifies this digital change. It replaces scattered, paper-heavy workflows with automated, centralized digital platforms. This shift is not just an upgrade; it is vital for better control over quality processes, the need for real-time insights into performance, and the ongoing effort to simplify regulatory compliance across various regions.

This paper aims to analyze current trends in eQMS adoption within the pharmaceutical sector. It will look at the regulatory challenges of digitizing quality processes and highlight the essential requirements for strong software validation. Specifically, it will discuss the roles and validation considerations of commonly used eQMS tools, including Laboratory Information Management Systems (LIMS), SAP Quality Management (QM), and TrackWise QMS. Throughout this paper, it will reference global pharmaceutical guidelines to illustrate the regulatory landscape for this transformative change.

Electronic Quality Management Systems (eQMS): Foundations and Benefits:

An electronic Quality Management System (eQMS) is a digital platform built to help pharmaceutical Quality Assurance (QA) teams manage, track, and document all quality-related processes. It acts as a centralized digital storage for quality information, making operations smoother and ensuring compliance with various industry regulations, including Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP).[7]

Core Functionalities of eQMS :

A comprehensive eQMS typically incorporates several interconnected modules that automate and integrate key quality management functions:

- **Document Control:** A strong eQMS offers effective document management features. It makes sure that all important documents, such as Standard Operating Procedures (SOPs), policies, specifications, and batch records, are version-controlled, easy to access, and securely stored. This functionality is crucial for staying ready for audits and reducing the risks of using outdated or unapproved documents.[7]
- **Change Management:** The pharmaceutical industry is always changing due to new scientific discoveries, regulatory updates, and process improvements. An eQMS supports effective change management by providing structured workflows for starting, reviewing, approving, and carrying out changes. This makes sure that all modifications are well documented, assessed for risks, and communicated to all relevant stakeholders. As a result, it reduces the chances of compliance breaches and unintended consequences.[7]

- **Training Management:** Regulatory requirements state that all employees involved in GxP (Good Practice) activities must be properly trained. Their training records need to be up to date and easily accessible. An eQMS manages the scheduling, tracking, and documentation of training activities. This helps ensure that personnel are competent and that the organization complies with the latest industry standards and internal procedures.[7]
- **Corrective and Preventive Actions (CAPA):** The CAPA process is essential for ongoing improvement in pharmaceutical quality management. eQMS platforms help QA teams manage CAPAs effectively by offering tools for systematic root cause analysis, creating strong action plans, tracking implementation progress, and verifying effectiveness. This organized approach ensures that quality issues are addressed and prevented from happening again. It promotes a culture of continuous improvement.[7]
- **Audit Management:** An eQMS simplifies the entire audit process. This includes planning and scheduling audits, carrying them out, recording findings, and following up on actions. It offers a central system for managing internal and external audits. This ensures that all findings are addressed and documented, which helps maintain compliance.[32]

Key Drivers and Benefits of Digitizing Quality:

The adoption of eQMS and the broader digitalization of quality processes offer a multitude of benefits that address the inherent challenges of traditional systems:

- **Enhanced Efficiency and Productivity:** Automating repetitive tasks like document routing, review, and approval cycles cuts down on manual effort and lowers the chance of human error. This improvement saves valuable time for QA professionals. They can then concentrate on more strategic tasks such as risk assessment, process optimization, and proactive quality improvement.[7]
- **Real-time Reporting and Enhanced Data Visibility:** Digitalization allows for real-time monitoring and control of manufacturing processes and quality parameters. This gives immediate insights into operational data and improves data visibility across the organization. Access to current, accurate information helps with proactive decision-making and enables quick identification and response to deviations, preventing minor issues from getting worse.[11]
- **Improved Quality Control:** Using digital tools like AI-powered analytics helps eQMS predict and possibly prevent quality issues before they occur. This proactive method lowers the chances of product recalls and improves the overall safety and effectiveness of pharmaceutical products.[11]
- **Increased Agility and Flexibility:** Digital technologies help manufacturers quickly respond to changes in market demand, new regulatory requirements, or scientific insights. This greater flexibility supports rapid prototyping and speeds up product development. As a result, pharmaceutical companies can introduce new therapies to the market faster and adjust production scales when necessary.[11]
- **Simplified Regulatory Compliance and Audit Readiness:** By centralizing all quality documents and using workflows with features like electronic signatures and strong version control, an eQMS makes sure that essential documents are always ready for audits. This greatly lessens the difficulty and stress of preparing for and going through regulatory inspections. It allows for quick and reliable access to the necessary documentation.[7]
- **Lower Product Losses:** Digitalization offers precise control over the environment and allows for real-time monitoring. This is especially important in pharmaceutical manufacturing, where sensitive products need stable conditions. For example, digital platforms can reduce the risks tied to freezer temperature fluctuations. If these issues are not handled properly, they could result in millions of dollars lost in product.[12]

The adoption of eQMS is increasingly seen by regulatory bodies as more than just a tool for compliance. It is now viewed as a key factor in improving a company's Quality Management Maturity (QMM). The U.S. Food and Drug Administration (FDA) and other international standards organizations are actively encouraging the use of new technology. They recognize its strong link to effective quality management practices. For example, the FDA plans to assess QMM using an optional rating system in the future. This suggests that adopting eQMS can offer a strategic edge. It can affect a company's future standing with regulators and its position in the market. This view changes eQMS from just a compliance expense to an important investment in organizational quality and readiness for the future.[34]

Despite the clear benefits, fully digitizing quality management comes with challenges. The many digital options available can be overwhelming, and there is a high risk of facing a costly learning curve during deployment. Additionally, the financial commitment needed for implementing an electronic Quality Management System (eQMS) can be a major barrier, especially for smaller pharmaceutical companies. Integrating new eQMS solutions with existing legacy IT systems, like Enterprise Resource Planning (ERP) or Manufacturing Execution Systems (MES), also involves significant technical complexities. These factors show that successfully adopting eQMS requires not just technological investment but also strong strategic planning, good change management, and often, the help of outside experts to reduce deployment risks and ensure smooth integration throughout the organization.[13]

Emerging Trends and Technological Advancements in eQMS:

The pharmaceutical industry has historically lagged behind other key sectors in digital progress. Now, it is quickly adopting digital changes in its R&D, manufacturing, and quality processes. This shift is fueled by the need for increased agility, improved efficiency, and accurate real-time control over complex operations. This transformation is significantly affecting electronic Quality Management Systems (eQMS). Several new technologies are being added to build smarter and more responsive quality systems.

Integration of Advanced Technologies within eQMS:

- **Artificial Intelligence (AI) and Machine Learning (ML):** AI and ML are becoming key parts of modern eQMS, allowing a major shift from reactive to proactive quality management. These technologies examine large datasets from manufacturing equipment and processes to predict potential malfunctions or product quality problems before they happen. AI also automates document control workflows, improves auditing by identifying high-risk areas, and personalizes training programs based on individual employee needs and knowledge gaps. Beyond quality operations, AI is changing drug discovery by speeding up molecule screening and design, which could significantly cut development timelines and costs.[15]
- **Internet of Things (IoT):** IoT sensors play a key role in monitoring important parameters in pharmaceutical manufacturing. These include temperature, humidity, pressure, and vibration. The constant flow of data offers quick alerts for any changes outside the set ranges. This allows for fast action and active quality control. Maintaining exact environmental conditions and quickly spotting issues helps reduce product losses and ensures steady product quality.[11]
- **Cloud Computing:** Cloud-based eQMS solutions offer unmatched scalability and flexibility. They provide storage options that promote easy collaboration, quick data access, and better data management for teams spread around the world. This model lets organizations grow their QMS capabilities without needing large upfront investments in infrastructure. It also allows remote access for managing quality while on the move.[10]
- **Blockchain:** This distributed ledger technology improves traceability and greatly lowers the chances of data tampering by providing unchangeable records throughout the pharmaceutical supply chain, from raw material sourcing to final product distribution. Each transaction is recorded and time-stamped, ensuring data integrity and security. This is essential for verifying product origin, fighting counterfeiting, and enabling efficient recalls.[16]
- **Digital Twins:** Digital twins are virtual copies of physical processes, equipment, or complete manufacturing facilities. These twins receive real-time sensor data from their physical counterparts. This data allows for simulation, monitoring, and improvement of drug production processes. Pharmaceutical companies can use this technology to test new formulations, simulate changes in processes, and predict how manufacturing equipment will perform. This approach helps reduce risks and costs before implementing changes in the real world.[12]

The Role of eQMS in Supporting Patient-Centricity and Personalized Medicine :

Modern eQMS, especially those using AI and real-world data, are essential for personalized medicine and patient-centered healthcare. They promote a deeper understanding of products and improve treatment effectiveness. The use of AI and IoT in eQMS allows a shift from reactive to proactive quality management. This shift helps predict equipment failures, quickly spot deviations, and allows for early detection of issues in the supply chain. As a result, it reduces waste and speeds up time to market. The real power of technologies like AI, IoT, cloud computing, and blockchain in eQMS comes from their combined use, creating a single digital ecosystem. For example, IoT data saved in the cloud is analyzed by AI/ML for predictive insights, while blockchain ensures data integrity and traceability. This requires a complete digital transformation plan for pharmaceutical companies to fully benefit from digitized quality.[10]

Regulatory Frameworks and Data Integrity in eQMS Adoption:

Data integrity is fundamental to quality assurance in the pharmaceutical industry. It guarantees that all data, whether created by hand or through electronic means, is complete, consistent, accurate, trustworthy, and reliable throughout its lifecycle. The widely accepted principles of ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available) serve as the foundation for managing both paper and electronic records. These principles provide a common standard for data quality and reliability.[5]

Key Global Guidelines Governing Electronic Records and Computerized Systems :

The adoption of eQMS necessitates strict adherence to a complex web of global and regional regulatory guidelines:

- **USFDA 21 CFR Part 11:** This regulation, created by the U.S. Food and Drug Administration (FDA), outlines the criteria for when electronic records and electronic signatures can be seen as trustworthy, reliable, and legally the same as paper records and handwritten signatures. It requires strong controls to guarantee the authenticity, integrity, and confidentiality of electronic data. This includes rules for unique user identification, detailed audit trails that track all changes, and secure connections between electronic signatures and the records they support. Recent FDA guidance from 2024 further explains the risk-based approach to validating electronic systems and emphasizes the need for improved controls to maintain data integrity.[1]

- **EMA Annex 11:** The European Medicines Agency (EMA) guideline, Annex 11, applies to all computerized systems used in Good Manufacturing Practice (GMP) activities in the European Union. It highlights the importance of managing risks throughout the lifecycle of a computerized system, from design to retirement. Key requirements include verifying personnel qualifications, setting up formal agreements with third-party suppliers, and conducting thorough system validation. It also requires strong data integrity controls, secure audit trails, effective change management processes, strict security measures, and electronic signatures that are legally equivalent to handwritten signatures.[6]
- **ICH E6(R2/R3):** The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines focused on Good Clinical Practice (GCP). These guidelines are essential for data integrity and using electronic systems in clinical trials. ICH E6(R2) highlights risk-based quality management and validating electronic systems used in clinical investigations. The updated ICH E6(R3) also includes technological advances, patient-centered approaches, and modern trial methods. This reinforces the critical importance of data integrity and the scientific soundness of trial design to ensure credible and accurate results.[2]
- **PIC/S PI 011-3 & PI 041-1:** The Pharmaceutical Inspection Co-operation Scheme (PIC/S) provides clear guidance on computerized systems and data integrity. This guidance is widely accepted around the world. PI 011-3 lays out the requirements for computerized systems in GMP environments. It highlights the need for risk assessment to define the scope of validation and ensure GxP compliance. PI 041-1 focuses on Good Practices for Data Management and Integrity. It details principles like ALCOA+ and stresses the need for strong data governance systems throughout the data lifecycle.[3,4]
- **WHO Guidelines (TRS 996 Annex 5):** The World Health Organization (WHO) guidance on Good Data and Record Management Practices (GDRP), found in Technical Report Series (TRS) 996 Annex 5, restates the ALCOA+ principles. It offers clear definitions for key terms like raw data, source data, metadata, and a "complete data set." The guideline requires risk-based system design and controls to find errors and omissions. It highlights the need for audit trails, secure data storage, and regular reviews of systems and procedures to maintain ongoing effectiveness.[5]
- **ANVISA (RDC 658, IN 134, Guide No. 33):** Brazil's National Health Surveillance Agency (ANVISA) has made Computer System Validation (CSV) a legal requirement within its regulations. RDC 658 outlines the basic principles of validation for GMP. Normative Instruction (IN) 134 provides additional GMP requirements for computerized systems used in medicine manufacturing and follows PIC/S guidelines. ANVISA's Guide No. 33 helps clarify the CSV steps. It incorporates the ISPE GAMP5 framework and classifies software and hardware to guide specific validation methods based on risk and complexity.[9,25]
- **SAHPRA (MCC) Guidelines:** The South African Health Products Regulatory Authority (SAHPRA), formerly the Medicines Control Council (MCC), requires compliance with Good Manufacturing Practice (GMP) guidelines that include specific demands for computerized systems. SAHPRA's guidelines stress the importance of having written procedures for validation. They ensure access security, data integrity, and maintain thorough records of all changes and deletions in computerized systems. SAHPRA's requirements match international best practices, including ICH and EU guidelines. They are also a member of PIC/S, which helps maintain consistency with global standards.[8]

Challenges in Navigating and Complying with Diverse and Evolving Regulatory Requirements :

Pharmaceutical companies face the challenge of aligning their eQMS implementations with various global and regional regulatory requirements. These guidelines are constantly changing to keep up with new technologies and advanced data management practices. This requires a solid understanding of each guideline's details and a flexible, risk-based approach to compliance that can respond to the changing regulatory environment.

Looking at the guidelines from USFDA, EMA, ICH, WHO, PIC/S, ANVISA, and SAHPRA shows a significant convergence on fundamental principles, such as ALCOA+ for data integrity and using risk-based methods for validation. This suggests a global agreement on the basic principles of good data management and system validation. However, each agency also has its specific regulations, sometimes with unique interpretations or extra requirements. For example, ANVISA has its detailed GAMP5 categorization in Guide No. 33. This indicates that while a foundational, globally aligned eQMS strategy is possible, companies operating internationally must still navigate and carefully manage these local nuances and specific legal interpretations to ensure full compliance. It is not a "one-size-fits-all" solution but rather a "single framework with local adjustments."

Moreover, the changing definition of "record" places more demands on eQMS design and validation. ICH E6(R3) defines "Source Documents and Data Source Records" as "original documents or data (that include relevant metadata) or certified copies... no matter the media used." Similarly, WHO stresses defining "raw data, source data, metadata, and a 'complete data set'." This explicitly acknowledges metadata—data about data, like who made a change, when it was made, and why—as an essential part of the record itself. For eQMS, this means that simply capturing primary results is not enough; the system must also record the context, history, and audit trail of that data to meet regulatory expectations for trustworthiness and retrievability. This calls for strong system design and validation efforts to ensure thorough metadata capture and permanence.

The growing dependence on third-party vendors for computerized systems also adds a layer of shared responsibility. EMA Annex 11, PIC/S, and ANVISA Guide No. 33 all clearly state the role of "Suppliers and Service Providers" when third parties are involved in supplying, installing, or maintaining computerized systems. Formal agreements and regular audits of these suppliers are required. The FDA's 2024 guidance also provides recommendations for working with IT service providers. This collective focus highlights that in a digital landscape, quality and compliance responsibilities extend beyond the pharmaceutical company's internal processes to its entire IT supply chain. Companies cannot merely outsource technology and distance themselves from accountability; they must actively manage and audit their vendors to ensure that the outsourced systems and services meet regulatory requirements for data integrity and system validation. This adds an important layer of complexity to vendor selection and ongoing management. [18,23]

The overview of the Global Pharmaceutical Guidelines for Computerized Systems and data integrity is outline in Table 1.

Table 1: Overview of Global Pharmaceutical Guidelines for Computerized Systems and Data Integrity

Guideline/Authority	Primary Focus	Key Requirements/Principles
USFDA (21 CFR Part 11)	Electronic Records & Signatures	ALCOA+, Risk-Based Approach, Audit Trails, Electronic Signatures, System Validation, Unique User Identification [1,17]
EMA (Annex 11)	Computerized Systems in GMP	Risk Management (throughout lifecycle), Personnel Qualifications, Formal Supplier Agreements, Data Integrity Controls, Audit Trails, Change Management, Security, Electronic Signatures [6,20]
ICH (E6 R2/R3)	Clinical Trial Data Integrity	Risk-Based Quality Management, Validation of Electronic Systems, Patient-Centric Approaches, Scientific Soundness, Metadata Inclusion [2,29]
WHO (TRS 996 Annex 5)	Good Data & Record Management	ALCOA+, Risk-Based System Design, Audit Trails, Secure Data Storage, Periodic System Review, Definition of Raw/Source/Metadata [5]
PIC/S (PI 011-3, PI 041-1)	Computerized System Validation & Data Integrity	Risk Assessment for Validation Scope, GxP Compliance, ALCOA+, Data Governance, Supplier Oversight, Inventory Listing [3,4]
ANVISA (RDC 658, IN 134, Guide No. 33)	GMP for Computerized Systems	CSV as Legal Requirement, GAMP5 Alignment (Categories 3, 4, 5), Data Integrity Proof, Supplier Competence & Trust, User Interaction Levels [9]
SAHPRA (GMP Guidelines)	Computerized Systems in GMP	Written Validation Procedures, Security of Access, Data Integrity, Record of Changes/Deletions, Alignment with ICH/EU/PIC/S [8]

Software Validation: Ensuring eQMS Reliability and Compliance:

Computer System Validation (CSV) is an essential and documented process. It ensures that computer-based systems consistently produce data and information that meet set requirements. In the pharmaceutical industry, this is vital for ensuring product quality, patient safety, and following regulatory guidelines. CSV is a key part of a company's commitment to quality assurance and showing compliance to regulatory authorities.[17]

Risk-Based Approach to Validation :

A key principle for nearly all global regulatory bodies is the risk-based approach to validation. This principle states that the level and thoroughness of validation efforts should match the risk the computerized system presents to patient safety, data integrity, and product quality. This approach makes sure that resources are used wisely and targeted on the most important parts and features of the eQMS. It helps maximize compliance while improving efficiency.[18,19]

- **GAMP 5 Guidelines :**

The ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems is a widely adopted framework that provides practical, risk-based guidance for achieving compliant computerized systems in regulated environments. It emphasizes a scalable lifecycle approach, promoting critical thinking by subject matter experts to define appropriate validation strategies. GAMP 5 also highlights the increasing use of software tools and automation to enhance control, improve quality, and reduce risks throughout the system's lifecycle. The framework categorizes software (e.g., Category 3: non-configured products, Category 4: configured products, Category 5: customized applications) and hardware (e.g., Category 1: standard hardware, Category 2: embedded custom hardware) to guide the appropriate level of validation effort required for each component.[17]

The Validation Lifecycle (IQ, OQ, PQ) :

The validation process for computerized systems usually follows a set lifecycle. This ensures that an eQMS is suitable for its intended use, starting from the design phase, through its operational life, and ending with its retirement. This lifecycle typically includes three separate qualification phases.:

- **Installation Qualification (IQ):** This documented process confirms that the eQMS software, hardware components, and related infrastructure are installed correctly based on the manufacturer's specifications and the system's design requirements. IQ activities typically involve checking package contents against packing lists, verifying physical installation in the correct location, confirming connections to other devices, ensuring proper power supply, and verifying that operating conditions and the environment meet specifications.[28]
- **Operational Qualification (OQ):** Following successful IQ, OQ checks that the eQMS works as it should within its specified operating range. This phase includes thorough functional testing of all system features and setting the operational parameters of the device. It ensures that the system operates consistently and reliably within these defined limits, testing elements like displays, controls, and measurement systems. [28]
- **Performance Qualification (PQ):** PQ offers documented proof that the eQMS works consistently as intended in real operating conditions, using actual data and trained staff. This important step confirms that the system meets user needs and generates reliable, accurate results over time. PQ usually includes detailed sampling plans, following specific acceptance criteria, and testing in the actual facility with the utilities, equipment, and manufacturing processes intended for commercial operations. [28]

The Computer System Validation (CSV) Lifecycle Phases and GAMP 5 alignment is outline in Table 2.

Table 2: Computer System Validation (CSV) Lifecycle Phases and GAMP 5 Alignment

Phase	Objective	Key Activities	GAMP 5 Alignment
Installation Qualification (IQ)	Verify correct installation of software, hardware, and components.	Cross-checking against packing list; Physical installation verification; Connection checks; Power supply verification; Environmental condition matching.	Ensures foundational setup meets specifications, aligning with GAMP 5's emphasis on documented installation and initial verification. [28]
Operational Qualification (OQ)	Verify system operates as intended across its specified operating range.	Functional testing of all system features; Establishing operational parameters (e.g., controls, displays, measurements); Confirming consistent performance within limits.	Confirms functional specifications are met, with testing proportionate to risk, as advocated by GAMP 5's risk-based approach to functional testing. [28]
Performance Qualification (PQ)	Verify consistent performance under actual operating conditions with real-world data.	Testing with trained personnel and actual materials; Extensive sampling plans; Adherence to predefined acceptance criteria; Confirmation of user requirements fulfillment.	Provides documented evidence that the system is fit for intended use in the operational environment, a core GAMP 5 principle for ensuring quality and compliance. [28]

Essential Validation Controls and Documentation:

To ensure the reliability and compliance of eQMS, several essential controls and documentation elements are required throughout the validation lifecycle:

❖ **User Requirements Specification (URS):** This is a crucial document that outlines both the functional and non-functional needs of the system from the user's perspective. It serves as a roadmap for the entire validation process. It specifies necessary functions, performance criteria, security requirements, data integrity needs, and user access controls.

❖ **Validation Master Plan (VMP):** This document outlines the overall strategy for Computer System Validation across an organization. It details objectives, roles and responsibilities, timelines, and required resources. This ensures a systematic and controlled approach to all validation activities.

❖ **Traceability Matrix:** This important tool connects each requirement specified in the URS to corresponding validation tests (IQ, OQ, PQ). It ensures thorough verification, proving that all system requirements have been effectively tested and validated. It also provides a clear audit trail for compliance purposes.

❖ **Standard Operating Procedures (SOPs):** Detailed, step-by-step instructions for performing validation tasks are found in SOPs. These procedures ensure accuracy, consistency, and uniformity in all validation activities. This is especially important in regulated environments where the integrity of the system's validated status relies on following established protocols.

❖ **Audit Trails:** Secure, unchangeable records of all system activities are essential. Audit trails capture every data creation, modification, or deletion, giving details on who performed the action, when it occurred, and why the change happened. This function is critical for maintaining data integrity and for reconstructing events while demonstrating accountability to regulatory bodies.

❖ **User Access Controls:** Strong, role-based security features are implemented to limit access to specific functions and data based on assigned user permissions. This stops unauthorized manipulation of data and sensitive information, which improves system security and data integrity.

- **Data Backup and Recovery Procedures:** Thorough procedures for data backup and recovery are necessary to ensure data durability and consistent availability. These measures protect against data loss in case of system failures, disasters, or other unforeseen circumstances, allowing for the reconstruction of study data and related information.
- **Electronic Signatures:** To be legally equivalent to handwritten signatures, electronic signatures must be unique to each person, securely linked to the electronic record, and include the printed name of the signer, the date and time of execution, and the meaning associated with the signature (e.g., authorship, review, or approval). Regulatory bodies like the FDA (21 CFR Part 11) and EMA (Annex 11) outline their requirements for implementation.

The field of software validation is continuously changing. While traditional IQ, OQ, and PQ methodologies remain vital for manufacturing processes, approaches to software validation are shifting toward a more modern, risk-based method called Computer Software Assurance (CSA). This trend, especially noted in the MedTech industry, indicates a wider movement in regulated environments. GAMP 5 emphasizes "critical thinking by knowledgeable and experienced SMEs" and "evolving approaches to software development." This suggests that the traditional, often heavily documented, IQ/OQ/PQ approach for software is becoming more streamlined and risk-related, moving toward a more efficient and less burdensome "assurance" model. Pharmaceutical companies should prepare for this shift, possibly adopting more agile validation methods to speed up software deployment while ensuring compliance.

One direct result of digitalizing quality is the increased feasibility and benefit of "paperless validation." Regulatory bodies like ANVISA highlight paperless validation as a better strategy for compliance. They cite benefits like time savings, improved management of digital data, greater agility through parallel workflows, and reduced validation costs by removing the need for physical paperwork, printing, and storage. The ability to conduct remote validations further shows the efficiency gained. This illustrates how digitalization changes the validation process itself, making it more efficient, cost-effective, and audit-ready, thus removing a traditional barrier to innovation and technology adoption within the pharmaceutical sector.[18,21,24]

10. eQMS Software Tools in Pharmaceutical Industries: LIMS, SAP, and TrackWise :

The pharmaceutical industry uses various specialized eQMS software tools to manage different aspects of quality. Some of the most notable are Laboratory Information Management Systems (LIMS), SAP Quality Management (QM), and TrackWise QMS. Each offers unique but often complementary functions.

- **Laboratory Information Management Systems (LIMS) :**

A Laboratory Information Management System (LIMS) serves as the central hub for pharmaceutical laboratories. It integrates various processes, instruments, and data points into a unified digital framework. Its main functions streamline laboratory operations and ensure data integrity. These include sample registration, tracking, and chain of custody management from receipt to final disposition, efficient test assignment and scheduling, accurate results capture and validation, seamless instrument integration for automated data collection to reduce manual errors, strong inventory management, and detailed audit trails.

LIMS is essential for maintaining data integrity and following regulations, particularly with USFDA 21 CFR Part 11, in quality control (QC) labs. It centralizes data and applies strict controls like access permissions, role-based security, and secure electronic signatures. This reduces manual errors and provides a solid structure for showing compliance during audits and inspections. LIMS allows real-time monitoring of data trends and statistical process control, supporting proactive quality improvement by identifying potential issues before they affect product quality.

- **SAP Quality Management (QM) :**

SAP Quality Management (QM) is an integrated module within SAP ERP systems, like SAP S/4HANA, widely used in the pharmaceutical industry. It covers quality planning, inspections, audits, and quality control processes throughout the entire value chain, from procurement to production and distribution. SAP QM offers features for sample management and batch release, embedding quality checks into procurement, manufacturing, and distribution workflows. This ensures that quality is part of all business processes, not just a separate function.

SAP QM is crucial for maintaining product quality and Good Manufacturing Practice (GMP) compliance. It manages incoming material inspections, in-process quality checks, and critical batch release procedures. The module supports electronic records and signatures while complying with USFDA 21 CFR Part 11. It provides detailed audit trails and customizable workflows, making the SAP system a reliable source for regulatory inspections. This system also facilitates quick batch recalls when needed by ensuring end-to-end traceability.

- **TrackWise QMS :**

TrackWise QMS is a top-tier on-premises Quality Management System software that centralizes all quality processes. It provides a complete view of compliance and operational efficiency across an enterprise. TrackWise offers industry best-practice workflows and is highly configurable to meet existing processes and specific compliance needs. Its main functions include a variety of quality event management tasks, such as

Corrective and Preventive Actions (CAPA), change control, audit management, complaint handling, deviations, document management, training management, and supplier quality management. TrackWise stands out for its ability to integrate with other enterprise systems like ERP, CRM, LIMS, MES, and PLM. This integration ensures real-time data flow and smooth workflows, which are essential for responding to regulatory changes and market shifts. Newer versions, like TrackWise Digital, include AI-enabled features such as auto-summarization and auto-categorization to aid decision-making and promote proactive quality. They also support hybrid cloud deployments for added flexibility.

The Comparative Analysis of LIMS, SAP QM, and TrackWise QMS Core Functionalities is outline in Table 3.

Table 3: Comparative Analysis of LIMS, SAP QM, and TrackWise QMS Core Functionalities

Feature/ Functionality Area	LIMS	SAP QM	TrackWise QMS
Data Integrity & Compliance	Robust audit trails; 21 CFR Part 11 compliance; Access controls; Electronic signatures; Centralized data management. [1]	GMP compliance; 21 CFR Part 11 support; Audit trails; Electronic signatures; Embedded quality checks. [22,27]	Comprehensive quality event management; Regulatory compliance reporting; AI-enabled data integrity monitoring. [14]
Sample Management	End-to-end sample lifecycle tracking; Registration, tracking, chain of custody; Test assignment & scheduling. [26]	Sample management features integrated into quality planning and inspection processes. [22,27]	Can integrate with LIMS for comprehensive sample data management. [14]
Quality Control & Inspection	Results capture & validation; Instrument integration; Real-time monitoring of data trends; Statistical Process Control (SPC). [26]	Quality planning; Incoming material inspections; In-process quality checks; Final product inspections. [22,27]	Quality data and actionable insights; Trend identification; Proactive problem prevention. [14]
Batch Release	Provides data for batch release decisions; Supports audit trails for lab data. [26]	Integrated batch release workflows; Manages usage decisions for batches; Aggregates data from various systems (ERP, LIMS, MES) for accelerated release. [22,27]	Supports product quality review and management of nonconformance for batch release. [14]
CAPA & Deviation Management	Supports data collection for CAPA; Integrates with QMS for comprehensive management. [1]	Can record quality notifications/defects; Built-in workflows for deviations, investigations, and CAPA. [22,27]	Comprehensive CAPA system; Manages deviations in centralized location; Automated routing, notification, escalation. [14]
Document Control	Focuses on test results, sample data, analytical reports; Supports ISO certification. [1]	Supports documentation for production and quality processes; Electronic records and audit trails. [33]	Robust document management system; Version control, accessibility, security; Centralized platform for SOPs, change control records. [34]
Training Management	Not a primary focus, but data can support training needs. [1]	Not a primary focus, but can integrate with HR modules. [22]	Automates scheduling, tracking, and documentation of training; Ensures personnel competency and compliance. [32]
Audit Management	Provides audit trails for lab data. [1]	Supports quality auditing processes integrated with ERP. [22]	Streamlines audit process (planning, execution, findings, follow-up); Integrated tracking and workflow engine. [32]
Integration Capabilities	Integrates with laboratory instruments; Can complement QMS. [26]	Integrates with MM, PP, SD modules; Can integrate with LIMS and MES. [22]	Integrates with ERP, CRM, LIMS, MES, PLM; Real-time interoperability. [14]
AI/ML Adoption	LIMS systems with AI integration enhance data integrity. [30]	Supports predictive quality management through IoT sensors and AI. [31]	AI-enabled quality (auto-summarization, auto-categorization, autocorrelation); Shift to proactive quality. [14]

The need for interoperability in a unified digital quality ecosystem is a common theme among these eQMS tools. LIMS systems connect with laboratory instruments. SAP QM integrates with LIMS and Manufacturing Execution Systems (MES). TrackWise links with various enterprise systems, including ERP, CRM, LIMS, MES, and Product Lifecycle Management (PLM). This strong focus on integration is not just a feature; it is essential for a truly digital quality system in the pharmaceutical sector. Without smooth data flow between these specialized systems, information silos remain, which undermines the benefits of digitalization, like real-time visibility, thorough data analysis, and data-driven decision-making. This shows that pharmaceutical companies should prioritize eQMS solutions with strong API capabilities and a clear integration plan to develop a connected and efficient quality ecosystem. They should avoid ending up with a collection of isolated digital tools. The different primary focus areas of LIMS, SAP QM, and TrackWise QMS create a strategic challenge for pharmaceutical companies when choosing an eQMS. LIMS specializes in detailed laboratory data and sample management, meeting the specific needs of QC labs. SAP QM is excellent at embedding quality checks within enterprise-wide processes like procurement and manufacturing, ensuring quality is part of daily operations. TrackWise, on the other hand, serves as a complete QMS, managing a wide range of quality events and workflows across the organization. While these systems are significant in "digitizing quality," their different primary focuses mean there is no one "right" eQMS solution for every organization. The best choice depends on a company's current IT setup, specific quality management needs, level of digital maturity, and strategic goals. This shows that adopting an eQMS is a strategic decision that requires thoughtful consideration of specialization versus integration.[14,26,27]

CONCLUSION

The pharmaceutical industry is experiencing a significant change as it adopts electronic Quality Management Systems (eQMS) to digitize its quality processes. This shift aims to improve efficiency, enhance data visibility, and maintain product integrity. It is transforming quality management from a reactive role to a proactive, data-driven practice. Technologies like Artificial Intelligence (AI), the Internet of Things (IoT), cloud computing, blockchain, and digital twins are increasingly being incorporated into eQMS. This integration allows for predictive quality management, real-time monitoring, better traceability, and scalable data management across global operations. The success of adopting eQMS is closely tied to strong Computer System Validation (CSV) practices and ongoing compliance with a complex, yet harmonious, global regulatory environment. Frameworks such as ISPE GAMP 5 offer vital guidance for a risk-based approach to validation. They ensure that eQMS tools, whether specialized like LIMS or comprehensive like SAP QM and TrackWise, reliably produce accurate data. Global regulatory bodies like the USFDA (Part 11), EMA (Annex 11), ICH (E6 R2/R3), WHO (Annex 5), PIC/S (PI 011-3, PI 041-1), ANVISA (IN 134, Guide No. 33), and SAHPRA (GMP Guidelines) highlight the key principles of data integrity (ALCOA+), the importance of solid audit trails, secure electronic signatures, and thorough supplier oversight. The changing definition of "record" to include metadata further emphasizes the need for systems that capture and preserve the full context of data, ensuring it can be reconstructed and trusted. Looking ahead, the digital quality management landscape will continue to change quickly. The growing sophistication of AI applications will promote further automation and predictive abilities, leading toward autonomous quality control. The need for greater interoperability among different systems (like LIMS, ERP, MES, QMS) will remain essential for creating a truly unified digital quality ecosystem. This will help eliminate data silos and provide comprehensive insights. Regulatory frameworks will keep evolving to match technological progress, requiring ongoing attention and adjustments from pharmaceutical companies. Future investments should focus not only on advanced technology but also on building a workforce skilled in data science, validation methods, and regulatory compliance in a digital environment. Ultimately, the strategic adoption and strict validation of eQMS are crucial for pharmaceutical companies looking to maintain a competitive edge, guarantee high product quality and effectiveness, and ensure patient safety in an increasingly digitized global market.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Murray, John F., Davis Jerome , General Principles of Software Validation; Final Guidance for Industry and FDA Staff, Guidelines Data Integrity & Computer System Validation, 2002; (1.1):1-33. Available at: https://www.fda.gov/media/73141/download.

2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Q7), 2000 November;3(4):11-18. Available at : https://database.ich.org/sites/default/files/Q7%20Guideline.pdf.

3. Pharmaceutical Inspection Convention Pharmaceutical Inspection Co-Operation Scheme (PIC/S), PE 009-17 (Annexes), 2023 August; 8(1): 169-173, Available at : https://picscheme.org/docview/8881.

4. Pharmaceutical Inspection Convention Pharmaceutical Inspection Co-Operation Scheme (PIC/S), PI 011-3, Guide to Good Practices for Computerised Systems in Regulated GxP Environments, 2007 Sep, Available at: https://picscheme.org/docview/3444.

5. World Health Organization (WHO), Good Manufacturing Practices: Guidelines on Validation, Annex 3, Appendix 5 : Validation of computerized systems: 161-178, Available at: https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1019-annex3-gmp-validation.pdf

6. European Commission Health and Consumers Directorate-General, Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, EudraLex The Rules Governing Medicinal Products in the European Union, Volume 4, Annex 11: Computerised Systems, Available at: https://health.ec.europa.eu

7. *eQMS for pharma QA teams*, *IDBS*. Available at: https://www.idbs.com/knowledge-base/eqms-for-pharma-qa-teams/.

8. South African Health Products Regulatory Authority (SAHPRA), Guideline for Good Manufacturing Practice (GMP), SAHPGL-INSP-02, 2022 Sep, Version: 8, Available at: https://www.sahpra.org.za/document/guideline-for-good-manufacturing-practice/.

9. Brazilian Health Regulatory Agency (ANVISA), RDC (Resolução da Diretoria Colegiada) No. 658/2022 - Good Manufacturing Practices for

Medicines, RDC nº 658, de 30 de Março de 2022, Available at: https://www.gov.br/anvisa/pt-br/assuntos/regulamentacao/legislacao/busca/resolucao-rdc-no-658-de-30-de-marco-de-2022

10. *eQMS for Pharma Manufacturing*, *Master Control,* Available at: https://www.mastercontrol.com/quality/eqms-pharma/.
11. Kaplan, S. (2024) *Fueling innovation: The impact of digitalization in pharmaceutical manufacturing*, *Praxie.com,* Available at: https://praxie.com/digitalization-in-pharmaceutical-manufacturing/.
12. *Driving proactive decisions: How digitalization improves pharmaceutical manufacturers' new and existing facility performance*; *Manufacturing Tomorrow*, Available at: https://www.manufacturingtomorrow.com/news/2025/03/28/driving-proactive-decisions-how-digitalization-improves-pharmaceutical-manufacturers-new-and-existing-facility-performance/24611.
13. Team, G.I.E. (2024), *Electronic Quality Management Systems - EQMS*, *GMP Insiders,* Available at: https://gmpinsiders.com/electronic-quality-management-systems-eqms/.
14. *Trackwise Digital Quality Management software* (2024) *Honeywell,* Available at: https://www.spartasystems.com/trackwise/.
15. Artificial Intelligence in Pharmaceuticals and Biotechnology: Current Trends and Innovations, Coherent Solutions, 2025 July, Available at: https://www.coherentsolutions.com/insights/artificial-intelligence-in-pharmaceuticals-and-biotechnology-current-trends-and-innovations.
16. Eleap Software, Digital transformation and quality management systems (QMS), Available at : https://www.eleapsoftware.com/digital-transformation-and-quality-management-systems-qms/.
17. PMC, Computer system validation in the pharmaceutical industry: An essential guide, Available at : https://pmc.ncbi.nlm.nih.gov/articles/PMC11416705/.
18. Compliance Online, Computer System Validation, Available at: https://www.complianceonline.com/dictionary/computer_system_validation.html.
19. Clinical Leader, Breaking down the FDA's latest guidance on electronic systems in clinical investigations, Available at: https://www.clinicalleader.com/doc/breaking-down-the-fda-s-latest-guidance-on-electronic-systems-in-clinical-investigations-0001.
20. Gilsinp, GUIDELINES Data Integrity & Computer System Validation, Available at: https://gilsinp.ru/?wpfb_dl=290.
21. Clinion, EMA Guidelines Whitepaper, Available at: https://www.clinion.com/whitepapers/EMA_Guidelines_whitepaper.pdf.
22. Intuition Labs (2025) *SAP in the pharmaceutical industry: Enterprise Solutions for drug development and manufacturing*, *Intuition Labs*, Available at: https://intuitionlabs.ai/articles/sap-in-pharma-industry.
23. ACRP. ICH E6(R2) to ICH E6(R3) Comparison, 2025 Jan 28, Available at: https://acrpnet.org/wp-content/uploads/2025/01/ICH-E6R2-to-ICH-E6R3-Comparison-01.28.25.pdf.
24. Five Validation, Drug serialization and traceability, Available at: https://fivevalidation.com/drug-serialization-and-traceability/.
25. Hahm, S., *Whitepapers*, *KAYE*., Available at: https://www.kayeinstruments.com/en/knowledge-library/technical-papers.
26. Bradley, C., *Role of laboratory information management systems (LIMS) in pharma*, *Lab Manager*, Available at: https://www.labmanager.com/role-of-laboratory-information-management-systems-lims-in-pharma-34153.
27. Intuition Labs. *SAP in the pharmaceutical industry: Enterprise Solutions for drug development and manufacturing*, *IntuitionLabs*. 2025. Available at: https://intuitionlabs.ai/articles/sap-in-pharma-industry.
28. Wingate Guy, Et al., GAMP 5*:* A risk-based approach to compliant GXP Computerized Systems, International Society for Pharmaceutical Engineering , 2008, (1)11:56.
29. Food and Drug Administration; Guidance for Industry Computerized Systems Used in Clinical Trials, Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/fda-bioresearch-monitoring-information/guidance-industry-computerized-systems-used-clinical-trials.
30. SNIC Solutions, LIMS Pharma, Available at: https://snicsolutions.com/blog/lims-pharma.
31. Ignite SAP, SAP Quality Management, Available at: https://ignitesap.com/sap-quality-management/.
32. GMP Insiders, Electronic Quality Management Systems (eQMS), Available at: https://gmpinsiders.com/electronic-quality-management-systems-eqms/.
33. Blog Soft Expert, RDC 658/22: Good Manufacturing Practices for Medicines, Available at: https://blog.softexpert.com/en/rdc-658-22-good-manufacturing-practices-for-medicines/.
34. Pharma QMS: Revolutionizing Quality Management in Pharmaceutical Manufacturing, Available at: https://nextplus.io/digital-transformation/pharma-qms-revolutionizing-quality-management-in-pharmaceutical-manufacturing/.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com

Corresponding Author's Biography: Dr. Nikhil Arun Vyawhare

Dr. Nikhil Arun Vyawhare is a respected pharmaceutical quality assurance expert, a prolific writer, and a thoughtful leader with more than 18 years of varied experience in the pharmaceutical Industry. Now living in Sungai Petani, Malaysia, his impressive career includes work at major pharmaceutical companies in both India and Malaysia. He shows a strong mix of scientific accuracy, strategic insight, and a deep commitment to quality.